Payment overview · 2025
General Payments
$1,378.44
93 reported records · 16 companies
Healthcare provider profile · identity verified
Jacobo Pena, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1598015620
Verified facts
What the public records show
CMS Open Payments records show Jacobo Pena, MD received $1,378.44 in general payments during 2025 across 93 reported records.
ABBVIE INC. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Linzess, Trelegy Ellipta, Trulance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $252.96 | 18.4% | 21 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $176.33 | 12.8% | 22 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $160.03 | 11.6% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $155.98 | 11.3% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.01 | 10.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.02 | 8.5% | 6 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $73.84 | 5.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.14 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.89 | 3.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.36 | 3.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.86 | 3.1% | 2 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $24.56 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.33 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.37 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.49 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.27 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,378.44 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $176.33 | 22 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $142.01 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.74 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $131.01 | 8 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $119.38 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $117.02 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $117.02 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $98.26 | 8 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $73.84 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $73.84 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $73.84 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $68.33 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.14 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $63.96 | 9 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $61.77 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 160 |
| Omeprazole | Omeprazole | 299 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 55 |
| Naproxen | Naproxen | 189 | 53 |
| Metformin Hcl | Metformin Hcl | 179 | 65 |
| Meclizine Hcl | Meclizine Hcl | 159 | 56 |
| Ammonium Lactate | Ammonium Lactate | 154 | 38 |
| Losartan Potassium | Losartan Potassium | 151 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 46 |
| Gabapentin | Gabapentin | 150 | 52 |
| Doxepin Hcl | Doxepin Hcl | 144 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 32 |
| Montelukast Sodium | Montelukast Sodium | 133 | 52 |
| Diclofenac Sodium Er | Diclofenac Sodium | 119 | suppressed |
| Linzess | Linaclotide | 101 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 41 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 98 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 98 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 31 |
| Memantine Hcl | Memantine Hcl | 84 | 30 |
| Famotidine | Famotidine | 83 | 27 |
| Lisinopril | Lisinopril | 81 | 33 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 78 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 30 |
| Eliquis | Apixaban | 76 | 24 |
| Carvedilol | Carvedilol | 75 | 31 |
| Meloxicam | Meloxicam | 74 | 27 |
| Jardiance | Empagliflozin | 72 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 28 |
| Hydrocortisone | Hydrocortisone | 62 | 19 |
| Latanoprost | Latanoprost | 58 | 13 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Ozempic | Semaglutide | 54 | 14 |
| Ketoconazole | Ketoconazole | 53 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 23 |
| Simvastatin | Simvastatin | 51 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 19 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Furosemide | Furosemide | 48 | 19 |
| Vascepa | Icosapent Ethyl | 47 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 46 | 13 |
| Glimepiride | Glimepiride | 44 | 17 |
| Single Use Swab | Alcohol Antiseptic Pads | 44 | 14 |
| Ibuprofen | Ibuprofen | 42 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 17 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | 11 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Valsartan | Valsartan | 36 | 15 |
| Fluocinonide | Fluocinonide | 35 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Restasis | Cyclosporine | 30 | 12 |
| Clotrimazole | Clotrimazole | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Xiidra | Lifitegrast | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,378.44 · 93 records | ABBVIE INC. | BOTOX, CREON, Cologuard Collection Kit, GEMTESA, GLYCATE, LEQVIO, LINZESS, MOUNJARO, MOVANTIK, NURTEC ODT, OTEZLA, QULIPTA, RELISTOR, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Symbravo, TRELEGY ELLIPTA, TRULANCE, The Cologuard Plus Collection Kit, UBRELVY, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error